Amyloidosis Project ECHO
Building the next generation of amyloidosis physicians.
The Amyloidosis Project ECHO has been created to address disparities and challenges in Amyloid Care Delivery.
Project ECHO (Extension for Community Healthcare Outcomes), developed at the University of New Mexico, is a collaborative learning model for medical education that enables expert healthcare teams to provide best-practice education to non-specialist healthcare providers through case-based learning and videoconferencing technology.
This virtual interactive clinic offers quarterly 1-hour sessions focused on AL (light chain) and TTR (transthyretin) amyloidosis, two underrecognized but increasingly manageable causes of heart failure and multisystem disease.
Each session includes:
- Brief didactic lectures (20 minutes) on suspicion, diagnosis, and management
- Case-based learning from real-world scenarios (20 min)
- Interactive Q&A (20 min) with amyloidosis specialists
Over the course of the Amyloidosis Project ECHO program, participants will be to:
- Recognize the clinical red flags for AL and TTR amyloidosis
- Understand the diagnostic pathways, including lab tests and imaging
- Apply evidence-based treatment strategies for both AL and TTR types
- Improve coordination of care with amyloidosis centers and specialists
- Reduce diagnostic delays and improve patient outcomes
Upcoming
Systemic Immunoglobulin Light Chain (AL) Amyloidosis: Detection and Diagnosis
February 25, 2026 | 6 PM EST
Didactic Speaker:
Sabrina Browning, MD
Assistant Professor of Medicine, Section of Hematology/Department of Internal Medicine
Smilow Cancer Hospital/Yale Cancer Center
Yale University School of Medicine
Objectives:
• Provide an overview of the pathophysiology of light chain (AL) amyloidosis.
• Review the clinical presentation and organ-specific manifestations of AL amyloidosis.
• Highlight the importance of having a high index of suspicion and identify common challenges in recognizing AL amyloidosis.
• Describe the recommended diagnostic workup for suspected AL amyloidosis including amyloid subtyping.
Present a Case
Well-prepared case presentations are essential to the long-term success of ECHO. When a new case is submitted to an ECHO project, the ECHO coordinator(s) will review it to ensure the case form has been completed correctly. Once reviewed, the case will be sent to the appropriate Hub members for presentation, and we will reach out to confirm we have received your case and provide presentation logistics.
Hub Team
Kaushik Ghosal, PhD
Director, Strategic Partnership and Business Development
Amyloidosis Research Consortium
Jose Nativi-Nicolau, MD
Advanced Heart Failure & Transplant Cardiologist
Mayo Clinic (Florida)
Johana R. Fajardo DNP, NE-BC, ANP-BC, FHFSA
Director Precision Cardiomyopathy Clinical Services
Advanced Heart Failure and Transplant Nurse Practitioner
Duke University Heart & Vascular Institute
Johanna Contreras, MD, MSc, FACC, FAHA, FASE, FHFSA
Cardiologist
Mount Sinai Hospital
Ahmad Masri, MD, MS
Associate Professor of Medicine, Division of Cardiovascular Medicine
Oregon Health & Science University
Ike Okwuosa, MD
Assistant Dean of Medical Education
Associate Professor, Medicine (Cardiology)
Northwestern Medicine
Michaela Liedtke, MD, CKD
Family Professor, Department of Medicine
Clinical Chief, Division of Hematology
Co-Director Stanford Amyloid Center
Co-Director Stanford Adolescent and Young Adult (SAYAC) Program
Stanford Health Care-Stanford Hospital
Mori Gertz, MD, M.A.C.P.
Consultant, Division of Hematology, Roland Seidler Jr. Professor Department of Medicine
Mayo Distinguished Clinician
Clinical Assistant
Mayo Clinic (Minnesota)
Sabrina Browning, MD
Assistant Professor of Medicine, Section of Hematology/Department of Internal Medicine
Smilow Cancer Hospital/Yale Cancer Center, Yale University School of Medicine
Michael Polydefkis, MD
Associate Professor of Neurology
Johns Hopkins
Yessar Hussain, MD
Neurologist
Austin Neuromuscular Associates
Dianna Quan, MD
Director, Electromyography Laboratory
Director, Neuromuscular Medicine Fellowship
University of Colorado
Sami L. Khella, MD
Professor of Neurology
Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine
This program has been supported by ASPIRE: Amyloidosis Stakeholder Partnerships for Impact, Reach and Equity. ASPIRE is an industry collaborative initiated by ARC in 2021 to facilitate a multi-stakeholder partnership model of innovation and engagement by providing a framework that centers ARC as a neutral convener to bring organizations together outside of the context of any specific marketed products or products in development to partner on or commission key initiatives to advance the field. ARC is a nonprofit, tax-exempt organization launched in 2015 to accelerate progress and improve the quality of life for patients with amyloidosis. It achieves this by changing the way research is conducted and driving greater focus on innovation, collaboration, and services that facilitate discovery and rapid advancement for the amyloidosis community.
For any questions or inquiries, please email Megan Glynn, Project ECHO Coordinator at mglynn@arci.org
